Zhejiang Beta Pharma Cancer Drug Shows Quicker, Cheaper Prospects
This article was originally published in PharmAsia News
China's Zhejiang Beta Pharma is working on icotinib for treating non-small cell lung cancer that in some quarters is considered a harbinger of new cancer drugs that could developed quickly and cheaply in China, according to an editorial in a medical journal.
You may also be interested in...
Abbott reported strong sales for diagnostics and devices in the third quarter and raised its full-year EPS guidance to $3.55 per share.
Vifor CEO Stefan Schulze tells Scrip that an expanded deal with Korsuva developer Cara Therapeutics means the US biotech will not have to invest in a commercial organization as the Swiss firm will mobilize its well-established sales force to launch the treatment for dialysis patients with CKD-associated pruritus.
A randomized trial demonstrated the superiority of Medtronic’s DTM spinal cord stimulation waveform over conventional spinal cord stimulation for treating back pain.